Grifols (GRFS) informs that its board has held an extraordinary meeting this afternoon “without the intervention of the conflicted board members.” Following the recommendation of the transaction committee, the board concluded that a potential offer by Brookfield Asset Management (BAM) of EUR 6.45B for the entire outstanding share capital of the company, implying an indicative price of EUR 10.50 per share, “significantly undervalues the Company’s fundamental prospects and its long-term potential.” Accordingly, the board would not recommend Grifols shareholders accept a potential offer at the indicated price.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRFS:
- Grifols doses first patient in Phase 1 trial of GIGA-2339
- Grifols price target raised to EUR 10 from EUR 9 at Deutsche Bank
- Grifols holder Mason Capital opposes potential transaction, tells board
- Grifols SA Reports Strong Third Quarter Growth
- Grifols reports Q3 adjusted EBITDA of EUR 462M, up 26.7% in constant currency